Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that the first participant has been dosed in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback